CN1016693B - 新顺铂铬合物的制备方法 - Google Patents
新顺铂铬合物的制备方法Info
- Publication number
- CN1016693B CN1016693B CN87104027A CN87104027A CN1016693B CN 1016693 B CN1016693 B CN 1016693B CN 87104027 A CN87104027 A CN 87104027A CN 87104027 A CN87104027 A CN 87104027A CN 1016693 B CN1016693 B CN 1016693B
- Authority
- CN
- China
- Prior art keywords
- acid
- phenyl
- platinum
- hydroxyl
- divalence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000008569 process Effects 0.000 title claims abstract description 14
- 229910052804 chromium Inorganic materials 0.000 title description 2
- 239000011651 chromium Substances 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- -1 nitro, carboxyl Chemical group 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 3
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical group [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 abstract description 5
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 3
- 239000000460 chlorine Substances 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 235000011167 hydrochloric acid Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003518 caustics Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000003934 aromatic aldehydes Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 150000007522 mineralic acids Chemical group 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- KNURWXWPWSONGI-UHFFFAOYSA-N 4-phenyl-1,3-dioxan-5-amine Chemical compound NC1COCOC1C1=CC=CC=C1 KNURWXWPWSONGI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 229910021612 Silver iodide Inorganic materials 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- RXEOUPRDNFPRRV-UHFFFAOYSA-N anisole;methanamine Chemical compound NC.COC1=CC=CC=C1 RXEOUPRDNFPRRV-UHFFFAOYSA-N 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- ANORDWOIBSUYBN-UHFFFAOYSA-N n-chloro-1-phenylmethanamine Chemical compound ClNCC1=CC=CC=C1 ANORDWOIBSUYBN-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100001223 noncarcinogenic Toxicity 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical compound C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 1
- UYTMLDBQFLIQJA-XQRVVYSFSA-N (nz)-n-(furan-2-ylmethylidene)hydroxylamine Chemical compound O\N=C/C1=CC=CO1 UYTMLDBQFLIQJA-XQRVVYSFSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- DORVKAJYRZXVMJ-UHFFFAOYSA-N 2-bromobutanediamide Chemical class NC(=O)CC(Br)C(N)=O DORVKAJYRZXVMJ-UHFFFAOYSA-N 0.000 description 1
- HNQLMBJUMVLFCF-UHFFFAOYSA-N 4-chloro-1,2-dimethylbenzene Chemical compound CC1=CC=C(Cl)C=C1C HNQLMBJUMVLFCF-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical class ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000036312 Juniperus coahuilensis Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical class [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001492 aromatic hydrocarbon derivatives Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical class [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UTWYCVYPCQKRDR-UHFFFAOYSA-N n-methyl-n-phenylhydroxylamine Chemical compound CN(O)C1=CC=CC=C1 UTWYCVYPCQKRDR-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical class [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及通式(I)表示的具有小鼠抗肿瘤活性的新顺铂二氨铬合物及其制备过程,上述式(I)中取代基的定义与说明书相同。本发明还涉及以上述化合物为活性成份的小鼠抗肿瘤组合物以及这些化合物在制备小鼠抗肿瘤药剂中的用途。
Description
本发明涉及新顺铂络合物、含有它们作为活性成份的抗小鼠肿瘤组合物、以及制备这些化合物的方法。
1965年罗斯伯里(Rosenberg B.)等人偶然发现了顺式二氯二氨合铂(Ⅱ)(以下简称顺铂)[Rosenberg Bet al.,Nature250(1965)698],并报导了该化合物对Sarcoma和Leukemia L的抗肿瘤活性[Rosenberg B.et al.,Nature222(1969)385],1978年底美国食品及药物管理局正式批准顺铂为抗癌药以治疗睾丸癌和子宫癌。不久又被获准治疗膀胱癌。
顺铂虽是目前较好的抗癌药之一,但毒性很强,其中对神经、胃和肾的毒性尤其明显,它与其它抗癌药物一样,亦有致癌和不育等涉及对DNA作用的慢性毒性。
迄今,顺铂类似物已合成了不下1500种以上,所谓第二代顺铂类似物即该类似物上氨基取代基,是各种类型脂族基团的取代氨基顺铂类似物,此类衍生物中有些已获专利保护(见美国专利4,410,544)。
前人在此领域虽做了大量研究,但疗效堪与顺铂相提并论的药物至今未曾出现,至于如何降低抗癌药物本身的致癌性问题,由于机理不明,仍属难题。
发明人根据本人提出的双区理论[Scientia Sinica(1979)964-977]进而从事探寻非致癌性抗癌药的工作,并致力于新的毒性低、非致癌的顺铂衍生物的研究。双区理论认为,致癌作用的关键步骤是DNA互补碱对间的横向交联。为了加强抗癌剂对正常细胞和癌细胞作用的选择性,设计的抗癌剂应起到降低上述交联趋势,加强非互补碱间交联的作用。
发明人对改变顺铂类似物上的取代基进行了广泛研究,合成了一系列任意取代的芳基、杂芳基取代的烷基或环烷基二氨合铂(Ⅱ)和(Ⅳ)络合物,发现上述化合物具有卓越的抗肿瘤活性,本发明化合物的特点是任意取代的芳基、杂芳基团与络合物中心金属原子间存在一脂肪键结构,有效地防止了络合物中心金属原子与非脂族取代基间电子的离域作用。
顺铂类似物通常难溶于水和有机溶剂,因此不易被肠吸收,根据不同的给药方式,有时它们难于显示抗肿瘤活性,药物在腹腔投予后,难以达到治疗目的。本发明化合物的溶解度较已知的顺铂类似物为佳在抗小鼠的肿瘤中是有效的,用简单的给药方法和简单的配方就显示出优越的抗肿瘤活性。本发明以上述发现为依据,这些化合物是文献上未曾记载过的新化合物。
本发明提供了通式(Ⅰ)表示的顺式二氨合铂(Ⅱ)和(Ⅳ)络合物
其中,
Q1和Q2可以相同或不同,各自代表脂族基团,或饱和脂族杂环二价基团;
Ar1和Ar2可以相同或不同,各自代表芳族基团、杂芳族基团,或两者合在一起代表两价芳族基团或杂芳族基团;
R3和R4可以相同或不同,各自代表氢原子、C1-5烷基以及C1-10杂烷基;
X代表阴离子配位体如卤素阴离子配位体或二价阴离子配位体如有机或无机酸根,限制条件是:Z不存在以及X不是卤素则Ar1、Q1和R3中至少一个基团必须为含杂原子或含氧基团;
本发明还提供了含有上述一种或多种化合物为活性成份的抗肿瘤组合物,以及制备这些化合物及组合物的方法。下面对本发明作更为详细的描述。
本文中的术语脂族或饱和脂族杂环二价基团是指直链或支链脂族C1-5亚烷基或任意含一、二或更多个氧、氮或硫原子的脂族5至6元环,例如:
等,
芳基是指任意被一个或多个卤素(例如:氟原子、氯原子、溴原子或磺原子)、羟基、硝基、或羧基取代的苯基、萘基、菲基。
杂芳基是指任意取代的杂环基、环中至少一个杂原子是氧、氮或硫,所述杂环基团选自呋喃、吡咯、吡啶及噻吩基。
含氧基团是指羟基、羟甲基或羧基。
C1-5烷基是指直链或支链C1-5烷基,较好的是甲基、乙基、正丙基、异丙基,更好的是甲基。
术语卤素阴离子是指氟、氯、溴或碘阴离子,当X代表有机或无机酸根时,所述的酸根可以是下述酸根中的一个酸根,它们是:乙酸根、氯乙酸根、草酸根、马来酸根、1,2-苯二甲酸根、4-羟基-1,2-苯二甲酸根、环-1,1-丁二甲酸根、葡糖酸根及硫酸根。
通式(Ⅰ)表示的本发明化合物可用以下方程式表示的方法制备:
K2[PtCl4]+2Am→[PtAm2Cl2]+2KCl
或K2[PtCl4]+4KI→K2[PtI4]+4KCl
K2[PtI4]+2Am→[PtAm2I2]+2KI
[PtAmI2]+2AgNO3+H2O→[PtAm2(H2O2)](NO3)2+AgI↓
[PtAm2(H2O2)](NO3)2+2KX′→[PtAm2X2′]+2KNO3+2H2O
其中X′表示除碘离子以外的卤素阴离子,Am表示合成铂络合物所需的氨类配体。通式(Ⅰ)表示的化合物可以在溶剂存在下使氯亚铂酸钾与相应当量的氨基配体反应来制备,亦可先从氯亚铂酸钾制成相应的碘化物,再与硝酸银作用生成水合物,然后与所需的卤化钾交换,如果需要,可用乙酸、氯乙酸、草酸、丙二酸、羟基邻苯二甲酸、葡萄糖酸、硫酸等有机或无机酸进一步转换成相应的络合物。在上述方法所得的二价铂(Ⅱ)络合物中加入过量约30%H2O2在50-110℃的温度范围内反应可制成相应的四价铂络合物。
用于合成本发明化合物的溶剂可提及的有例如,水;含C1-5碳原子的醇类如甲醇、乙醇、丙醇,异丙醇、丁醇、叔丁醇、戊醇、优选的是乙醇;含C1-5个碳原子的酮类如丙酮;二甲基亚砜;二甲基甲酰胺,这些溶剂可单独或混合使用,其中优选用水。
反应温度可从10-50℃范围内进行选择,但特别可取的反应温度是室温。
反应时间可从0.5到24小时的范围内适当地选择。
反应完成后反应物用常规方法处理,例如,过滤、干燥,然后可以或无需用常规精制即得纯品。
可取的精制溶剂有二甲基亚砜,二甲基甲酰胺、丙酮、水或上述溶剂的混合物。
上述反应中作起始原料的一系列胺类配体,其中苄胺及其衍生物可以按下式用Leuckart反应制备;
其中R5为选自氢,卤素(氟、氯、溴),硝基,羟基,羟甲基,羧基,羧甲基,C1-4烷基的基团,P为1-3的整数。
该法描述于以下文献:来惠斯、美国化学会志(K.G.Lewis.J.Chem.Soc.)(1950)2247-2250,Leuckart法主要用于从酮制备脂族胺类,以芳香醛为原料时,则胺的收率很低。本发明的特点是在反应体系中加入过量甲酸并添加Raney镍催化剂,收率高于已有技术,从而使从芳醛合成苄胺的方法成为工业上可用的方法。
任意取代的呋喃甲胺及羟苯基甲胺的制备,采用相应醛肟在酸性介质中还原法,可用以下方程式表示;
R-CH=NOH ([H+])/(Zn+ACOH) R-CH2NH2
其中R表示任意取代的呋喃基、噻吩基或羟苯基。用于本反应的酸可提供及的有:有机或无机酸如醋酸、硫酸或盐酸等。
二齿胺类配体例如邻二氨甲芳烃衍生物的制备,可先将相应的原料二溴化生成邻二氨甲芳烃衍生物,再与邻苯二甲酰亚胺钠盐作用,用水合肼水解,可用下式表示:
4-苯基-5-氨基-1,3二氧六环可按下式例示的方法制备,该方法系发明人在下述文献中公布过的方法(Dai Qianhuan,Kexue Tongbao1977(9)381)
其中X表示氯或溴原子,然后用酒石酸与其成盐进行拆分,用常规方法进行后处理,得旋光异构体[R∶R]-(-)-4苯基-5-氨基-1,3-二氧六环,残剩物用甲醇重结晶可得其对映异构体,这一拆分方法系本发明首先提出。
本发明化合物的典型实例及部分铂络合物的溶解度列于表Ⅰ、Ⅱ、Ⅲ、Ⅳ及Ⅵ中,但本发明不受此限制。
实验测得的本发明化合物的抗肿瘤活性描述于下:
本发明化合物,特别是表Ⅰ、Ⅱ、Ⅲ、Ⅳ、所列的化合物对小鼠黑色素瘤、B16细胞株、Hela宫颈癌细胞和胃癌细胞MGC-803有高于顺铂的杀伤活性。对小鼠S180腹水及小鼠白血病L1210皆有治疗作用。
试验实施例1
对DBA/2种小鼠腹腔内接种L1210白血病细胞,其量为1×106细胞/小鼠。试验药在腹腔内给药一次(即在接种24小时后)对小鼠的存活或死亡观察30天,将试验组动物和对照组动物相比,其延命率(%)按下法获得,即将对照小鼠给以生理盐水之存活天数指定为100,其结果如表Ⅴ所示,对于部分溶解度较小的受试化合物是在受试化合物中加入少量表面活性剂(例如吐温80)以制得受试药混悬体。
试验实施例2
对DBA/2种小鼠腹腔内接种S180肿瘤细胞,其量约为1×106细胞/小鼠。试验药在腹腔内给药一次(即在接种24小时后)对小鼠的存活或死亡之观察30天,试验动物和对照动物存活时间之比(%)按下法获得,
即将对照小鼠给以生理盐水之存活天数指定为100,结果如Ⅴ所示,对于部分溶解度较小的受试化合物是在受试化合物中加入少量表面活性剂以制得受试药物悬浮体。
表Ⅴ
本发明化合物如上所述可望用作抗肿瘤制剂。本发明化合物可以口服给药或非肠道给药如皮下、静脉内、肌肉或腹膜或直肠给药。
根据采用的药物剂型及其它因素铂络合物在每单位药剂中的含量可有大幅度变化,但通常铂络合物的含量比可从0.01到100%,较好的是0.1到70%(重量百分比)药剂的其它组成部分是载体和佐剂。考虑到动物试验结果和各种情况,上述化合物可在一范围内连续或间竭给药,使其总剂量不超过某一水平,剂量可随给药途径和被治疗的患者或动物的状况(如年龄、体重、性别、敏感性、食物等)、给药间隔、与上述化合物联合使用的药物和病程而做适当改变。在某种状况下的最优剂量和给药次数必须由于医学专家来决定。
当口服给药时,本发明化合物可制成固体或液体制剂如胶囊、药片、锭剂、熔融剂、粉剂、溶液、悬浮液或乳液。固体剂型通常有如:胶囊或片剂。胶囊可以是通常的明胶型含附加的赋形剂如,表面活性剂,润滑剂及惰性填充料如乳糖,蔗糖以及玉米淀粉,本发明化合物亦可与通常的片剂基质如乳糖、蔗糖以及玉米淀粉及粘合剂,如阿拉伯胶,玉米淀粉或明胶,崩解剂如马铃薯淀粉或藻朊酸,以及润滑剂如硬酯酸镁合并制成片剂。
当非肠道给药时,可将化合物与生理可接受的稀释剂及药物载体相混制成溶液或悬浮液,当注射剂型给药时,则用适合的稀释剂或载体包括无菌液体如水或油,加或不加表面活性剂或其它药学上可接受的佐药,本发明实践中可应用的各种油作为例子的有:动物油、植物油或合成来源的油例如,花生油、豆油及矿物油等。一般来说水,盐水、右旋糖酐的水溶液及有关糖溶液,乙醇及二醇如丙二醇或聚乙二醇是较好的液体载体,特别适宜用于制备注射溶液。
以下具体实施例将进一步阐明本发明,但本发明不受此限止。
实施例1
对氯苯甲胺的制备
于三口并中加入25克甲酸胺,18,4克甲酸,1克Raney镍,加热至125-130℃搅拌下于半小时内滴加13.7克对氯苯甲醛,升温至140-145℃反应3小时。冷却后加入浓盐酸调节pH值至<3,回流2小时。冷却后用氢氧化钠液中和至强碱性,水蒸汽蒸馏,馏出液收集于浓盐酸(18%W/V)与水的混合液(1∶1)中,减压浓缩至干,残剩物用15%氢氧化钠水溶液碱化至取碱性,氯仿提取,有机层用水洗,无水硫酸镁干燥,浓缩,减压蒸馏得无色油状产物,收率51-67%。
同法用相应的取代苯甲醛可制备一系列苄胺衍生物。
实施例2
呋喃甲胺的制备
将10克用常规方法制得的糠醛肟加到75毫升95%乙醇和80毫升乙酸的混合液中,用水浴加
热,搅拌下分四次加入70克锌粉,搅拌5小时,放置过夜,反应液倾入400毫升水中,滤除残余锌粉,用20%氢氧化钠溶液碱化,乙醚提取,用固体氢氧化钠干燥,蒸馏,收集沸点为143℃的产物,收率56-63%(具酚基并易与甲酸反应的芳香醛均用此法制备相应的胺)
实施例3
4-氯-邻苯二甲胺的制备
0.1毫克分子4-氯-邻二甲苯,在干燥四氯化碳中与40克溴代丁二酰胺,0.5克过氧化二苯甲酰回流1.5小时,冷却,过滤后蒸去四氯化碳,加入100毫升二甲基甲酰胺,30克邻苯二甲酰亚胺钾,于90-100℃加热两小时,冷却,加入500毫升水,用氯仿提取三次,合并氯仿提取液,以水及氢氧化钠液洗涤,浓缩至结晶开始拆出,冷却,加入100毫升乙醚,干燥后过滤,得4-氯-1,2-二-[邻苯二甲酰亚胺甲基]苯,为无色结晶形产物。
在0.5克分子上述产物中加入100毫升乙醇,0.1毫升水合肼,回流2小时,加入50毫升浓盐酸,继续回流2小时,冷却至0℃,过滤,滤液减压浓缩至干,得固体,稀盐酸重结晶,得4-氯邻苯二甲胺二盐酸盐。总收率48-55%
同法用相应取代邻二甲苯可合成一系列邻苯二甲胺衍生物二盐酸盐。
实施例4
反式4-苯基-5-氨基-1,3-二氧六环的制备
在高压釜中加入反式4-苯基-5-氯-1,3-二氧六环(0.5克分子),以甲醇500毫升为溶剂,通入2克分子氨气(过量),在100大气压下150℃氨化,常规处理,得顺式4-苯基-5-氨基-1,5-二氧六环。收率:72%,沸点:170-172℃/4mmHg。
上述顺式4-苯基-5-氨基-1,3-二氧六环与等当量右旋酒石酸成盐,在水中重结晶四次,用氯氧化钠液碱化,乙醚提取,用无水硫酸镁干燥,蒸除乙醚,减压蒸馏得[R∶R]-(-)-4-苯基-5-氨基-1,3-二氧六环。[α]16 D=(-)65.2°,滤液合并后,浓缩至干,用甲醇重结晶六次,20%氢氧化钠液碱化,乙醚提取,干燥,蒸除乙醚后,减压蒸馏,得[S∶S]-4-苯基-5-氨基-1,3-二氧六环,[α]16 D=+62。
实施例5
顺式二碘-二邻氯苄胺合铂(Ⅱ)络合物的制备
83克(20毫克分子)氯亚铂酸钾溶液于200毫升水中,加入40克(240毫克分子)碘化钾饱和溶液,水浴加热至70℃,立即停止加热,避光放置1/2小时,过滤,滤液中加入邻氯苄胺44毫克分子,30℃搅拌至溶液变为无色。滤出沉淀,相继用水、乙醇、无水乙醇洗涤,真空干燥,得纯净的题述二碘-二邻氯苄胺合铂(Ⅱ)络合物,无需进一步精制即可得分析纯样品。如果需要,可将其溶于二甲基甲酰胺中,再加乙醇和水(1∶1)混合液,使结晶拆出,过滤,相继用水、乙醇、无水乙醇洗涤,真空干燥,收率80-84%
同法可制得表1中各相应化合物。
实施例6
顺式二氯-二(邻氯苯甲胺合)铂(Ⅱ)络合物的制备
实施例5制得的二碘化物5克,用少量水将其搅成糊状,取少于当量4%的硝酸银,将其溶于50毫升水中,搅拌下加入糊状物中,直至溶液中不能检出银离子(Ag+)为止,过滤除去碘化银,滤液中加入比等当量多10%的固体KCl,摇动,放置半小时,放入冰箱,半小时后过滤,相继用冰水、无水乙醇及无水乙醚淋洗,所得产品溶于二甲基甲酰胺中,用0.1N盐酸使沉淀析出,放入冰箱,2小时后过滤,沉淀用冰水、无水乙醇及无水乙醚洗,真空干燥,得淡黄色产物。
同法用相应原料可以制得表Ⅰ中各相应化合物。
实施例7
二氯二(对甲氧苯甲胺合)铂(Ⅱ)络合物的制备
4.2克氯铂酸钾(10毫克分子)溶于50毫升水中,过滤,除去可能的不溶物,滤液中加入对甲氧基苯甲胺(20毫克分子),30℃搅拌反应,直到溶液无色,滤出沉淀,将其溶于二甲基甲酰胺中,过滤,除去不溶的Magnus盐,加水使结晶析出,过滤,沉淀相继用水和乙醇淋洗,真空干燥。得产品。
实施例8
按实施例6的方法制得:二碘-二[R-(+)-α-苯乙胺合]铂(Ⅱ)络合物;二氯-二[R-(+)
-α-苯乙胺合]铂(Ⅱ)络合物;二磺-二[S-(-)-α-苯乙胺合]铂(Ⅱ)络合物;二氯-二[s1-α-苯乙胺合]铂(Ⅱ)络合物;
二碘-二[d1-α-苯乙胺合]铂(Ⅱ)络合物;
二氯-二[d1-α-苯乙胺合]铂(Ⅱ)络合物,以及列于表2中的其它相应化合物
实施例9
按实施例6的方法制得:
二碘-二[(R∶R)-(-)-4-苯-1,3-二氧六环胺基合]铂(Ⅱ)络合物;二氯-二[(R∶R)-(-)-4-苯基-1,3-二氧六环胺基合]铂(Ⅱ)络合物;二碘-二[S∶S)-(+)-4-苯基-1,3-二氧六环胺基合]铂(Ⅱ)络合物;二氯-二[S∶S)-(+)-4-苯基-1,3-二氧六环胺基合]铂(Ⅱ)络合物。
实施例10
按实施例6的方法制得二碘-二[呋喃甲胺合]铂(Ⅱ)络合物;二氯-二[呋喃甲胺合]铂(Ⅱ)络合物。
实施例11
按实施例6的方法用等当量相应的邻苯二甲胺为起始原料,制得表Ⅱ中所列的各化合物。
实施例12
按实施例6的方法制得相应的二碘-[二氨合]铂(Ⅱ)络合物,在其反应液中加入乙酸、氯乙酸、草酸、丙二酸、1,1-环丁二酸或羟基邻苯二甲酸等酸的银盐后,减压浓缩,可制得表Ⅳ中所列的相应酸根络合物。
实施例13
反-羟基-顺二氯-二[对氯苄胺合]铂(Ⅳ)络合物的制备
按实施例7的方法制得二氯-二(对氯苄胺合)铂(Ⅱ)络合物,加入过量过氧化氢,约过量30%,于水浴95℃反应分钟,析出沉淀,用水洗涤,用二甲基甲酰胺精制,得黄色固体。同法可制得表Ⅲ中所列的各化合物。
表Ⅴ(a)
化合物 接种癌细 剂量 T/C
编号 胞种类
配位基 酸根 (mg/kg) %
(小鼠)
L1210 3.5 132
对照 Cis-PDD
S180 3.5 140
L1210 13.5 >161
S180 13.5 >184
L1210 13.5 >177
S180 13.5 >175
L1210 10 >182
S180 10 >140
L1210 10 >197
S180 10 >140
L1210 10 >210
S180 10 >202
L1210 8 >201
Ⅰ
I
S180
表Ⅴ(b)
化合物 接种癌细 剂量 T/C
编号 胞种类
配位基 酸根 (mg/kg) %
(小鼠)
L1210 8 >201
S180
L1210 17.5 >220
S180 17.5 >215
L1210 17.5 >246
Ⅰ29
Cl
S180 17.5 >250
L1210 17.5 >226
S180 17.5 >230
L1210 17.5 >260
Ⅰ31
Cl
S180 17.5 >245
L1210 15 >212
S180 15 >227
L1210 15 >238
S180 15 >251
表Ⅴ(c)
化合物 接种癌细 剂量 T/C
编号 胞种类
配位基 酸根 (mg/kg) %
(小鼠)
L1210 10 >243
S180 10 >230
L1210 10 >250
S180 10 >255
L1210 10 >175
S180 10 >180
L1210 10 >180
S180 10 >184
L1210 17.5 >150
Ⅰ
I
S180 17.5 >158
L1210 12 >205
S180 12 >198
L1210 17.5 >200
S180 17.5 >200
表Ⅴ(d)
化合物 接种癌细 剂量 T/C
编号 胞种类
配位基 酸根 (mg/kg) %
(小鼠)
L1210 12 >225
S180 12 >230
L1210 17.5 >215
S180 17.5 >220
L1210 12 >226
S180 12 >218
L1210 17.5 >168
S180 17.5 >175
L1210 12 >203
S180 12 >207
L1210 17.5 >190
S180 17.5 >198
L1210 12 >215
S180 12 >211
表Ⅴ(e)
化合物 接种癌细 剂量 T/C
编号 胞种类
配位基 酸根 (mg/kg) %
(小鼠)
L1210 17.5 >140
S180 17.5 >135
L1210 10 >196
S180 10 >202
L1210 10 >184
S180 10 >176
L1210 10 >212
S180 10 >215
L1210 10 >252
S180 10 >200
Claims (14)
1、制备通式(Ⅰ)化合物的方法,
其中,
Q1和Q2相同,代表直链或支链C1-5亚烷基、亚羟乙基、或任意含有二个氧的脂族6员环的二价基,
或二者合在一起代表二价苯基或由卤素、羧基取代的二价苯基、羟基取代的二价萘基、
R3和R4相同,代表氢原子;
X代表卤素、二价硫酸根、二价二羧有机根;Z代表羟基或不存在;条件是,Z不存在及X不是卤素,而Ar1或Ar2、Q1或Q2中至少一个基团含氧原子;该方法特征在于:
a.在10-50℃,于适宜溶剂中,将氯亚铂酸钾与相应当量氨基配体反应,或先将氯亚铂酸钾与碘化物反应生成相应的碘化物,然后再将得到的碘化物与硝酸银作用生成水合物,生成的水合物再与所需的卤化钾反应生成二价铂(Ⅱ)络合物,如需要,可用无机酸或有机酸将其进一步转换成其它络合物;
b.于50-110℃,将二价铂(Ⅱ)络合物与过量约30%的H2O2反应,生成四价铂络合物。
2、根据权利要求1的方法,其中X为卤素、二价硫酸根、二价二羧有机根,条件是Z不存在或为羟基。
3、根据权利要求1的方法,其中X表示丙二酸根或环丁-1,1-二酸根,Z为羟基或不存在。
4、根据权利要求1的方法,其中Ar1或Ar2是具有羟基或羧基的苯基。
6、根据权利要求1的方法,其中Ar1或Ar2是苯基、任意被一个或多个卤素、羟基、硝基、羧基、取代的苯基或羟基取代的二价苯基。
7、根据权利要求1的方法,其中Q1或Q2是含有二个氧的脂族6员环的二价基。
8、根据权利要求1的方法,其中Q1和Q2为C1-2亚烷基。
9、根据权利要求1的方法,其中溶剂为水;含C1-5碳原子的醇类如甲醇、乙醇、丙醇、异丙醇、丁醇、叔丁醇、戊醇、含C1-5碳原子的酮类如丙酮;二甲基甲酰胺,二甲基亚砜,这些溶剂可单独或混合使用。
10、根据权利要求9的方法,其中优选水做溶剂。
11、根据权利要求9的方法,其中优选乙醇做溶剂。
12、根据权利要求1的方法,其中所述的有机酸指乙酸、氯乙酸、草酸、丙二酸、羟基邻苯二甲酸、葡萄糖酸。
13、根据权利要求1的方法,其中所述的无机酸指硫酸。
14、根据权利要求1的方法,其中反应时间为0.5-24小时。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN87104027A CN1016693B (zh) | 1987-06-05 | 1987-06-05 | 新顺铂铬合物的制备方法 |
GB8813192A GB2209161B (en) | 1987-06-05 | 1988-06-03 | Cis-platinum-diamine complexes, anti-tumorous compositions containing them, and methods for their preparation |
US07/203,041 US5198564A (en) | 1987-06-05 | 1988-06-06 | Cis-platinum-diamine complexes and antitumorous compositions containing them, and process for their preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN87104027A CN1016693B (zh) | 1987-06-05 | 1987-06-05 | 新顺铂铬合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN87104027A CN87104027A (zh) | 1988-12-14 |
CN1016693B true CN1016693B (zh) | 1992-05-20 |
Family
ID=4814691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN87104027A Expired CN1016693B (zh) | 1987-06-05 | 1987-06-05 | 新顺铂铬合物的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US5198564A (zh) |
CN (1) | CN1016693B (zh) |
GB (1) | GB2209161B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
US7138520B2 (en) * | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
CA2643145C (en) * | 2006-02-24 | 2014-04-29 | Mallinckrodt Inc. | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates |
DE102007060918A1 (de) * | 2007-12-14 | 2009-06-18 | Rheinisch-Westfälische Technische Hochschule Aachen | Verfahren zur Herstellung von cycloplatinierten Platin-Komplexen, durch dieses Verfahren hergestellte Platin-Komplexe sowie deren Verwendung |
CN105541920A (zh) * | 2015-12-04 | 2016-05-04 | 罗梅 | 一种手性(R)-α-苯乙胺铂配合物晶体 |
CN105753922B (zh) * | 2016-02-05 | 2019-07-02 | 南开大学 | 用于肿瘤治疗四价铂糖基配合物及其制备方法 |
US10533029B1 (en) * | 2018-09-18 | 2020-01-14 | King Fahd University Of Petroleum And Minerals | Anticancer trans-diaminoplatinum(II) complexes of selenones |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053587A (en) * | 1973-04-13 | 1977-10-11 | Research Corporation | Method of treating viral infections |
GB2131020B (en) * | 1982-11-25 | 1986-10-01 | Gerald Edward Adams | Improvements relating to compounds useful in radiotherapy or chemotherapy |
US4565884A (en) * | 1983-05-10 | 1986-01-21 | Andrulis Research Corporation | Bis-platinum complexes as antitumor agents |
EP0167310B1 (en) * | 1984-06-27 | 1991-05-29 | Johnson Matthey Public Limited Company | Platinum co-ordination compounds |
NO860509L (no) * | 1985-02-23 | 1986-08-25 | Asta Werke Ag Chem Fab | Tumorhemmende (1,2-difenyl-etylendiamin)-platin(ii)-komplekser. |
-
1987
- 1987-06-05 CN CN87104027A patent/CN1016693B/zh not_active Expired
-
1988
- 1988-06-03 GB GB8813192A patent/GB2209161B/en not_active Expired - Lifetime
- 1988-06-06 US US07/203,041 patent/US5198564A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5198564A (en) | 1993-03-30 |
CN87104027A (zh) | 1988-12-14 |
GB8813192D0 (en) | 1988-07-06 |
GB2209161A (en) | 1989-05-04 |
GB2209161B (en) | 1991-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1026112C (zh) | 叔羟烷基黄嘌呤的制备方法 | |
CN1045088C (zh) | 用作pnp抑制剂的嘌呤和鸟嘌呤化合物 | |
CN1036920C (zh) | 含杂环碳酸衍生物 | |
CN1028992C (zh) | 1,4,-苯并硫杂吖庚因衍生物的制备方法 | |
CN1708481A (zh) | 作为抗微生物剂的n-烷基-4-亚甲基氨基-3-羟基-2-吡啶酮 | |
CN1121380C (zh) | 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物 | |
CN87103138A (zh) | 新的喹啉衍生物及其制备方法 | |
CN1552711A (zh) | 去氢骆驼蓬碱衍生物类化合物及其应用 | |
CN88101642A (zh) | 哌嗪基-杂环化合物 | |
CN1013198B (zh) | 抗肿瘤的磺酰脲衍生物的制备方法 | |
CN1232398A (zh) | Il-8受体拮抗剂 | |
CN1016693B (zh) | 新顺铂铬合物的制备方法 | |
CN1041943A (zh) | 吡咯并[3,2-e]吡唑并[1,5-a]嘧啶衍生物及含有上述成份的药物 | |
CN1151165A (zh) | 三萜衍生物及其药用组合物 | |
CN1023644C (zh) | 抗心律不齐药化合物的制备方法 | |
CN1161120C (zh) | 多环2-氨基噻唑体系在预防或治疗肥胖的药物制备中的用途 | |
CN1482118A (zh) | 新颖的5-羟基-3-羧酸酯吲哚类衍生物及其制备方法 | |
CN101037437A (zh) | Flazin类似物及其制备方法与应用 | |
CN1743316A (zh) | 2-取代苯基-4,4,5,5-四甲基-1,3-二氧基咪唑啉,它们的制备及在药物制备中的应用 | |
CN1243746C (zh) | 抑制血管生成的杂环化合物 | |
CN1049156A (zh) | 茚并吲哚化合物 | |
CN1896092A (zh) | 赖氨酸七叶皂苷及其制备方法和其用途 | |
CN1026115C (zh) | 新的s-腺苷基甲硫氨酸脱羧酶抑制剂的制备方法 | |
CN1651041A (zh) | 姬松茸水溶性小分子提取物及其制备工艺和用途 | |
CN1015457B (zh) | 5-(3-烷基-5-叔丁基-4-羟基苯基)-2-氨基-6h-1,3,4-噻二嗪的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C13 | Decision | ||
GR02 | Examined patent application | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |